Optimising mRNA-LNP Formulation with Automated Microfluidics

Particle Works is revolutionising the field of nanomedicine through the development of innovative automated microfluidic systems that have the potential to enhance the efficiency of the nanotherapeutic drug development pipeline. These advanced systems provide a walk-away approach that can optimise every stage of nanoparticle formulation, empowering researchers in their quest for optimal particle design. With these cutting-edge technologies, researchers can strive for particle perfection without being bogged down in the time-consuming and labour-intensive aspects of the formulation process.

Nanomedicine offers the prospect of new tools for healthcare, and one example is the recent successful development of vaccines based on mRNA-containing lipid nanoparticles (LNPs) that can effectively deliver nucleic acid-based therapeutics to in vivo target sites. The success of these and future LNPs lies in effective formulation development and process scale-up. Industry efforts – from screening through to manufacturing – are therefore focused on improving nanoparticle delivery, targeting and performance. 

The field of nanomedicine presents new opportunities for healthcare, such as the recent breakthrough in the development of vaccines utilising mRNA-containing lipid nanoparticles (LNPs) that efficiently deliver nucleic acid-based therapeutics to in vivo target sites. To ensure the continued success of these and other LNPs, it is essential to improve the formulation development and process scale-up. Thus, industry efforts are concentrated on enhancing nanoparticle delivery, targeting, and performance, from the initial screening stages to final manufacturing. The focus on advancing these critical aspects of nanomedicine is key to unlocking its full potential in the future of healthcare.

Lee Jeffries, Managing Director at Particle Works, commented: “Particle Works has used expertise gained over 20 years of microfluidics engineering to develop novel automated systems in response to customer demand for flexibility, accurate control and consistent day-to-day performance. A robust process is the key to improving the efficiency and potency of novel genomic medicines using LNPs, and our ground-breaking platforms have the potential to significantly accelerate their development, ultimately providing significant clinical benefits for many life-threatening diseases.”

More information online